BCL2L1 and Parkinson disease: Furthermore, delivery of the TAT-Bcl-xL peptide protected neurons from death in an in vitro and in vivo model of Parkinson’s disease (PD) providing some of the first evidence that CPPs can be used in models of chronic neurodegenerative diseases [53,54,55].